Two-year data (SUNFISH part 2 study) on the use of risdiplam for type 2 or type 3 spinal muscular atrophy (SMA) suggest ongoing benefit

Exploratory results of study (n=180) suggest in people aged 2-25 years with Type 2 or non-ambulant Type 3 SMA, gains in motor function observed with risdiplam at month 12 continued to improve or were maintained at month 24 across primary and secondary endpoint measures.

Source:

Biospace Inc.